March 07, 2024
Alkermes Announces Appointment of Nancy S. Lurker to Board of Directors
February 15, 2024
Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2023 and Provides Financial Expectations for 2024
January 03, 2024
Alkermes Announces Topline Results From Long-Term, Open-Label Safety and Durability of Treatment Effect Study of LYBALVI® (olanzapine and samidorpha...
More than 200 Alkermes employees recently took time out of their normal work day to contribute their time and talents to a variety of local Massachusetts nonprofit organizations as part of our fifteenth Alkermes in Action employee volunteer day.
In celebration of International Women's Day, three senior female leaders at Alkermes reflected on their career journeys and their efforts to inspire inclusion.
Alkermes employees work with urgency -- in the laboratory, in the clinic and in the community -- seeking to make a meaningful difference for people living with complex and difficult-to-treat diseases. For many of our employees, this work is part of their personal mission to help patients, families and communities.
Neuroscience
Olanzapine and samidorphan - Schizophrenia or Bipolar I Disorder (pediatric)
ALKS 2680 - Narcolepsy
Orexin Agonists - Non-Orphan Indications